The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.
In July, Novartis/Sandoz finally received the go-ahead from a federal appeals court to market Zarxio, the biosimilar to Amgen’s Neupogen. As the doors open for marketing of these “interchangeable biologics,” reimbursement challenges might be the next barrier to surmount.
In a press release yesterday, the chairman of the Biosimilars Council Bertrand C. Liang, said that the regulatory process for biosimilars is still a work in progress in the United States and is not far ahead enough to “support regulation related to coverage, coding and payment of interchangeables.” The council has urged CMS to hold back on Medicare Part B reimbursement for biosimilars.
According to the CMS, Medicare Part B payment for biologicals will be available upon FDA approval and each biological product will receive its own billing code. The payment, says the guidance, will be 6% add-on to the wholesale acquisition cost or the average sales price (ASP), as the case may be. This guidance refers to payment for biosimilar administration in an outpatient setting such as a physician’s office or clinic but not in a hospital outpatient setting. However, a problem with this is that biosimilars, which are expected to cost less than the reference product, would yield a lower payment to physicians. To counter the issue, CMS said that once ASP information is available for this biosimilar product, Medicare payment will equal the ASP for the biosimilar product plus 6% of the ASP for the reference product.
However, according to Liang, “Grouping all biosimilars together under one payment calculation and billing code, while using a different code for the reference product, creates confusion, making it difficult to write coverage policies.” He is of the opinion that this could even have an adverse impact on the future development of biosimilars.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More